Invention Grant
- Patent Title: Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
-
Application No.: US17573238Application Date: 2022-01-11
-
Publication No.: US12097241B2Publication Date: 2024-09-24
- Inventor: Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee: BRISTOL-MYERS SQUIBB COMPANY
- Current Assignee Address: US NJ Princeton
- Agency: Baker, Donelson, Bearman, Caldwell & Berkowitz PC
- Agent Robin L. Teskin
- The original application number of the division: US17198939 2021.03.11
- Main IPC: A61K38/18
- IPC: A61K38/18 ; A61K38/22 ; C07K1/107 ; C07K14/64 ; A61K38/00 ; A61K45/06 ; A61K47/64 ; A61P9/00
Abstract:
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
Public/Granted literature
- US20220211812A1 MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF Public/Granted day:2022-07-07
Information query
IPC分类:
